Which has preferable valuation & earnings, BIIB or PCVX?

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.12 $1.29B $5.65 37.02 Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is BIIB or PCVX more profitable?

Biogen has a net margin of 8.32% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 11.18% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Vaxcyte N/A -37.56% -33.62%

Does the media refer more to BIIB or PCVX?

In the previous week, Biogen had 9 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Biogen and 5 mentions for Vaxcyte. Biogen's average media sentiment score of 1.35 beat Vaxcyte's score of 1.34 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PCVX or ALNY?

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Vaxcyte. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.34 beat Alnylam Pharmaceuticals' score of 0.32 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, INSM or PCVX?

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 46.21 -$1.28B -$4.11 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is INSM or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Vaxcyte's return on equity of -37.56% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Vaxcyte N/A -37.56% -33.62%

Does the media refer more to INSM or PCVX?

In the previous week, Insmed had 15 more articles in the media than Vaxcyte. MarketBeat recorded 20 mentions for Insmed and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.34 beat Insmed's score of 0.87 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ROIV or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Vaxcyte N/A -37.56% -33.62%

Does the media refer more to ROIV or PCVX?

In the previous week, Roivant Sciences had 1 more articles in the media than Vaxcyte. MarketBeat recorded 6 mentions for Roivant Sciences and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.34 beat Roivant Sciences' score of 1.13 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, PCVX or INCY?

Incyte has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Incyte $5.82B 4.30 $1.29B $7.85 15.73

Is PCVX or INCY more profitable?

Incyte has a net margin of 27.71% compared to Vaxcyte's net margin of 0.00%. Incyte's return on equity of 29.93% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Incyte 27.71% 29.93% 22.88%

Does the media prefer PCVX or INCY?

In the previous week, Incyte had 6 more articles in the media than Vaxcyte. MarketBeat recorded 11 mentions for Incyte and 5 mentions for Vaxcyte. Incyte's average media sentiment score of 1.59 beat Vaxcyte's score of 1.34 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Vaxcyte (PCVX) Competitors

$60.22 +2.15 (+3.70%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$59.96 -0.26 (-0.43%)

As of 08:00 AM Eastern

Compare

PCVX vs. BIIB, ALNY, INSM, ROIV, and INCY

Should you buy Vaxcyte stock or one of its competitors? Vaxcyte's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vaxcyte compare to Biogen?

Biogen (NASDAQ:BIIB) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Biogen had 9 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Biogen and 5 mentions for Vaxcyte. Biogen's average media sentiment score of 1.35 beat Vaxcyte's score of 1.34 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.12	$1.29B	$5.65	37.02
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biogen has a net margin of 8.32% compared to Vaxcyte's net margin of 0.00%. Biogen's return on equity of 11.18% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Vaxcyte	N/A	-37.56%	-33.62%

Biogen presently has a consensus target price of $227.07, suggesting a potential upside of 8.57%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 42.81%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Biogen beats Vaxcyte on 12 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Alnylam Pharmaceuticals?

Vaxcyte (NASDAQ:PCVX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Alnylam Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Alnylam Pharmaceuticals	$3.71B	8.09	$313.75M	$5.38	41.75

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Vaxcyte. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.34 beat Alnylam Pharmaceuticals' score of 0.32 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte currently has a consensus target price of $86.00, indicating a potential upside of 42.81%. Alnylam Pharmaceuticals has a consensus target price of $393.86, indicating a potential upside of 75.36%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Vaxcyte has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Vaxcyte's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Vaxcyte on 12 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Insmed?

Insmed (NASDAQ:INSM) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Insmed had 15 more articles in the media than Vaxcyte. MarketBeat recorded 20 mentions for Insmed and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.34 beat Insmed's score of 0.87 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	46.21	-$1.28B	-$4.11	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

96.8% of Vaxcyte shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 3.3% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vaxcyte has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Vaxcyte's return on equity of -37.56% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Vaxcyte	N/A	-37.56%	-33.62%

Insmed has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Insmed currently has a consensus price target of $205.52, indicating a potential upside of 60.16%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 42.81%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insmed is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Vaxcyte beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Vaxcyte (NASDAQ:PCVX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaxcyte has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Vaxcyte	N/A	-37.56%	-33.62%

Roivant Sciences has higher revenue and earnings than Vaxcyte. Roivant Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,169.11	-$299.77M	-$0.53	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Roivant Sciences currently has a consensus target price of $35.14, suggesting a potential downside of 3.05%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 42.81%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Roivant Sciences had 1 more articles in the media than Vaxcyte. MarketBeat recorded 6 mentions for Roivant Sciences and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.34 beat Roivant Sciences' score of 1.13 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Vaxcyte compare to Incyte?

Vaxcyte (NASDAQ:PCVX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Incyte has a net margin of 27.71% compared to Vaxcyte's net margin of 0.00%. Incyte's return on equity of 29.93% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Incyte	27.71%	29.93%	22.88%

Incyte has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Incyte	$5.82B	4.30	$1.29B	$7.85	15.73

In the previous week, Incyte had 6 more articles in the media than Vaxcyte. MarketBeat recorded 11 mentions for Incyte and 5 mentions for Vaxcyte. Incyte's average media sentiment score of 1.59 beat Vaxcyte's score of 1.34 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 42.81%. Incyte has a consensus target price of $121.65, indicating a potential downside of 1.50%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities analysts plainly believe Vaxcyte is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

Incyte beats Vaxcyte on 12 of the 15 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCVX vs. The Competition

Export

Metric	Vaxcyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.64B	$3.73B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.56%	10.62%
P/E Ratio	-7.89	11.49	270.85	25.39
Price / Sales	N/A	1,165.64	559.91	70.90
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	2.94	17.19	11.06	6.51
Net Income	-$766.63M	-$13.19M	$3.45B	$347.22M
7 Day Performance	1.69%	0.95%	0.62%	1.27%
1 Month Performance	7.15%	2.67%	2.08%	2.72%
1 Year Performance	87.66%	54.03%	61.59%	21.85%

Vaxcyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCVX Vaxcyte	2.4489 of 5 stars	$60.22 +3.7%	$86.00 +42.8%	+84.2%	$8.64B	N/A	N/A	160	Positive News
BIIB Biogen	4.0414 of 5 stars	$207.13 -0.4%	$224.61 +8.4%	+50.9%	$30.72B	$10.03B	36.66	7,500	Positive News
ALNY Alnylam Pharmaceuticals	4.8236 of 5 stars	$216.98 -1.0%	$396.72 +82.8%	-50.0%	$29.33B	$4.80B	40.33	2,770
INSM Insmed	3.5159 of 5 stars	$134.75 +2.8%	$205.52 +52.5%	+0.4%	$28.63B	$606.42M	N/A	1,664
ROIV Roivant Sciences	1.635 of 5 stars	$35.78 -1.5%	$35.14 -1.8%	+205.8%	$26.14B	$8.26M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCVX) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxcyte (PCVX) Competitors